Covered recipient · General Payments record
PATRICK J MILLER
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2023–2024
$426.52
- Reported across 24 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $313.44 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $152.23 | 7 |
| Novo Nordisk AS | $32.27 | 2 |
| GlaxoSmithKline, LLC. | $29.67 | 2 |
| Tris Pharma Inc | $19.45 | 1 |
| PFIZER INC. | $18.23 | 1 |
| Lilly USA, LLC | $16.02 | 1 |
| Acerta Pharma LLC | $15.88 | 1 |
| Sumitomo Pharma America, Inc. | $15.21 | 1 |
| Amgen Inc. | $14.48 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $14.09 | 01/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105038445 | CMS |
| ABBVIE INC. | $27.03 | 02/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105038447 | CMS |
| ABBVIE INC. | $30.33 | 05/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105038449 | CMS |
| ABBVIE INC. | $29.37 | 07/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105038451 | CMS |
| ABBVIE INC. | $14.74 | 09/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105038453 | CMS |
| ABBVIE INC. | $22.61 | 10/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105038455 | CMS |
| ABBVIE INC. | $14.06 | 11/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105038457 | CMS |
| Amgen Inc. | $14.48 | 09/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117629988 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.88 | 08/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105789416 | CMS |
| GlaxoSmithKline, LLC. | $15.49 | 07/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116196226 | CMS |
| GlaxoSmithKline, LLC. | $14.18 | 11/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115819568 | CMS |
| Lilly USA, LLC | $16.02 | 10/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135279478 | CMS |
| Novo Nordisk Inc | $17.09 | 09/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096953053 | CMS |
| Novo Nordisk Inc | $15.18 | 09/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096570640 | CMS |
| PFIZER INC. | $18.23 | 05/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131548879 | CMS |
| Sumitomo Pharma America, Inc. | $15.21 | 06/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148891179 | CMS |
| Tris Pharma Inc | $19.45 | 11/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147219478 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2023, 2024
- Source files
- Dataset page · Bulk file · PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.